SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ANDRX (ADRX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Stephen D. French who wrote (21)8/22/1997 1:08:00 AM
From: PAUL ROBERT ST. ONGE   of 127
 
Dorine: Speaking from experience Andrx is still a buy. Andrx is still in the early growth stage as emerging drug delivery company, with products nearing approval, and expected additional filings. While stocks such as these are for not the faint of heart, they typically
provide returns unheard of in other sectors. The company has talented
management,a talented scientific team, and the most important factor, experience.

I encourage you to do your own research, and see for yourself. I firmly believe you will see the company's products come to fruition,
and earning's that will surpass all analyst targets. I believe you will see the stock trading in the 60-80 range, by early next year.
Providing we maintain reasonable market conditions.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News